NCT01081964终止2 期
A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 48
- 主要终点
- Safety
研究概览
简要总结
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
详细描述
The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy, active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl (400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired pneumonia of moderate severity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female >/= 18 years old
- •Documented fever (oral >100°F (37.8°C), tympanic >101°F (38.1°C)must be documented within the time frame of 24 hours prior to first dose through 24 hours after first dose of study drug
- •Community-acquired pneumonia of moderate severity (defined as PSI Risk Class II or III) requiring administration of antibiotics
- •Dyspnea and/or tachypnea (>20 breaths/minute)
- •Clinical diagnosis of pneumonia, as demonstrated by all of the following signs and symptoms:
- •new or increased cough
- •production of purulent sputum or a change in the character of sputum in subjects who normally have purulent sputum
- •auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (e.g., bronchial breath sounds, egophony, or dullness on percussion)
- •Females must be surgically sterile (e.g., tubal ligation, hysterectomy), post-menopausal at least 2 years, or if of childbearing potential, they must have a negative urine pregnancy test (β-human chorionic gonadotropin [β-hCG]) prior to randomization into the study. Males and females must agree that if they have intercourse that they will use at least two medically accepted methods of birth control (e.g., hormonal contraceptive, intrauterine device, spermicide, or condom) from study entry through 60 days after discontinuation of study drug treatment
- •Able to give written informed consent in a manner approved by the Institutional Review Board or Ethics Committee and comply with the requirements of the study
排除标准
- •Subjects must NOT meet any of the following exclusion criteria:
- •Received one or more doses of any systemic antibiotic in the last 2 weeks
- •Diagnosed with any other infection requiring systemic antibacterial therapy
- •Require long-term (>7 days) antibiotic therapy
- •Previous diagnosed condition that might mimic or complicate the course and evaluation of the infectious disease process (e.g., septic shock, bronchiectasis, lung abcess or empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic fibrosis, post-obstructive pneumonia, etc.)
- •Hypothermia (oral <96°F [35.6°C}, tympanic <97°F [35.9°C]
- •Hospitalization (inpatient) in the previous 60 days or infection presumably acquired in the hospital
- •Resident of a skilled nursing facility anytime in the previous 60 days or infection presumably acquired in a skilled nursing facility
- •Chronic infection with Hepatitis B
- •Any evidence of, or is a known carrier of , Hepatitis C antibody
- •Infection with Clostridium difficile
- •Immunocompromising illness, including known human immunodeficiency virus (HIV) positivity or AIDS, organ (bone marrow) transplant recipients, and hematological malignancy
- •Psychotic disease, peripheral neuropathy, and glucose-6-phosphate dehydrogenase deficiency; uncontrolled or poorly controlled diabetes. Diabetic subjects who are stable and on a stable course of antihyperglycemic agents for the past 3 months will be permitted in the trial.
- •High exposure to sunlight or ultraviolet radiation
- •Immunosuppressive therapy, including cancer chemotherapy or chronic use of corticosteroids (i.e., >20mg prednisone or equivalent per day for >/= 14 days within the last 6 months
- •History of renal or hepatic disease as defined by at least one of the following:
- •Calculated creatinine clearance <50 mL/min (any subject on dialysis must be excluded)
- •BUN >/= 30 mg/dL
- •ALT or AST > 3x ULN
- •Total bilirubin > 2x ULN
- •Alkaline phosphatase > 1.25x ULN
- •History of or current malabsorption conditions (i.e., short bowel syndrome, active Crohn's disease, celiac disease, etc.)
- •Neutropenia as defined by absolute neutrophil count <1000 cells/mm
- •Subjects with neutrophil counts as low as 500 cells/mm3 are permitted if the reduction can be documented to be due to the acute infectious process
- •Platelet count <75,000/mm
- •Subjects with platelet counts as low as 50,000/mm3 are permitted if the reduction is historically stable
- •Coagulation tests >1.5x ULN (PT, PTT, or INR). Subjects on anticoagulants with values > 1.5x ULN can be enrolled, provided these values are historically stable and within the therapeutic range
- •History of alcohol or drug abuse in the past 2 years
- •History of seizure or currently receiving anti-seizure medication anytime in the past year, or a seizure in the past year
- •History of ventricular arrhythmia
- •History of QTc prolongation (i.e., >450msec) or observed QTc measurement at screening > 450msec, or a history of additional risk factors for Torsade de Pointe, such as heart failure, hypokalemia, or familial history of Long QT syndrome
- •Require medications that may prolong the QTc interval
- •Require medications that affect absorption, including but not limited to sucralfate or cimetidine
- •Require treatment with theophylline, probenecid, vitamin K antagonists (other than warfarin; subjects must be on stable dose of warfarin and within therapeutic range)
- •Pregnant, planning to become pregnant, or breast feeding
- •Received any investigational drug or device within 30 days prior to study entry
- •Previously received zabofloxacin in a clinical trial
- •History of allergy or intolerability to fluoroquinolones
- •History of fluoroquinolone tendinopathy
- •Evidence of immediately life-threatening disease including, but not limited to current or impending respiratory failure, acute heart failure, shock, acute coronary syndrome, unstable arrhythmias, hypertensive emergency, acute hepatic failure, active gastrointestinal bleeding, profound metabolic abnormalities (e.g., diabetic ketoacidosis), or acute cerebrovascular events
- •Current condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the data
- •Unable or unwilling to adhere to sthe study specified procedures and restrictions
研究组 & 干预措施
Zabofloxacin 3 days
Experimental
Zabofloxacin 400mg for 3 days
干预措施: Zabofloxacin (Drug)
Levofloxacin 500mg
Active Comparator
Levofloxacin 500mg once daily for 7 days
干预措施: Levofloxacin 500mg (Drug)
Zabofloxacin 5 days
Experimental
Zabofloxacin 400mg for 5 days
干预措施: Zabofloxacin 400mg (Drug)
结局指标
主要结局
Safety
时间窗: Up to 35 days after first dose
Assess safety through monitoring of adverse events, ECGs, and the collection of conventional laboratory data (i.e., chemistry panel, CBC with differential, urinalysis)
次要结局
- Efficacy of the two dosing regimens of zabofloxacin(Up to 35 days after first dose)
研究者
相似试验
已完成
2 期
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCPrimary Biliary CholangitisNCT05239468Intercept Pharmaceuticals72
已完成
2 期
A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic SubjectsAsthmaNCT03622112AstraZeneca808
已完成
2 期
Total Occlusion Study in Coronary Arteries - 5Chronic Coronary Total OcclusionsNCT01753180Matrizyme Pharma Corporation76
已完成
1 期
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent SmokersSmoking CessationNCT00463918Pfizer73
招募中
3 期
Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid TherapyCholestasisPrimary Sclerosing CholangitisNCT04309773Assistance Publique - Hôpitaux de Paris104